Journal of Diabetes Research

Journal of Diabetes Research / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 8503754 | 17 pages |

db/db Mice Exhibit Features of Human Type 2 Diabetes That Are Not Present in Weight-Matched C57BL/6J Mice Fed a Western Diet

Academic Editor: Hiroshi Okamoto
Received12 May 2017
Revised24 Jul 2017
Accepted25 Jul 2017
Published06 Sep 2017


To understand features of human obesity and type 2 diabetes mellitus (T2D) that can be recapitulated in the mouse, we compared C57BL/6J mice fed a Western-style diet (WD) to weight-matched genetically obese leptin receptor-deficient mice (db/db). All mice were monitored for changes in body composition, glycemia, and total body mass. To objectively compare diet-induced and genetic models of obesity, tissue analyses were conducted using mice with similar body mass. We found that adipose tissue inflammation was present in both models of obesity. In addition, distinct alterations in metabolic flexibility were evident between WD-fed mice and db/db mice. Circulating insulin levels are elevated in each model of obesity, while glucagon was increased only in the db/db mice. Although both WD-fed and db/db mice exhibited adaptive increases in islet size, the db/db mice also displayed augmented islet expression of the dedifferentiation marker Aldh1a3 and reduced nuclear presence of the transcription factor Nkx6.1. Based on the collective results put forth herein, we conclude that db/db mice capture key features of human T2D that do not occur in WD-fed C57BL/6J mice of comparable body mass.

1. Introduction

Obesity is a major risk factor for insulin resistance, metabolic syndrome, and type 2 diabetes (T2D) [1, 2]. In the human population, body mass index calculations are often used to determine metabolic disease risk [3], with stratifications ranging from nonobese (18.5–24.9 kg/m2) to overweight (25–30 kg/m2) to obese (>30 kg/m2). Different metabolic disturbances and degrees of risk are often detected within each subgroup [3, 4]. Consequently, increasing body mass in the form of excess adiposity is often detrimental to whole body glucose homeostasis due to a chronic low-grade inflammatory condition [5].

On a cellular level, adipocytes play a key role in both fat storage and production of soluble factors that regulate insulin sensitivity [6]. In addition, whether excess intracellular lipid content is stored in adipose tissue or in lean tissues has major implications for disease risk [7, 8]. Storage of lipid in lean tissues is detrimental and produces adverse metabolic outcomes [7]. The chronic low-grade inflammation associated with an overabundance of adipose tissue often leads to endocrine alterations and dysfunction of other tissues, such as the skeletal muscle and liver [5].

During insulin resistance and “prediabetes”, islet β-cells typically increase in number via proliferation of the existing cellular population [911]. In addition, insulin output is enhanced prior to diabetes onset to compensate for reduced action of the hormone in peripheral tissues (e.g., skeletal muscle and liver). Once a decrease in islet β-cell insulin secretion and diminutions in the β-cell population or both occur, clinical onset of T2D ensues [12]. Clearly, there are stages of disease progression with earlier metabolic aberrations (e.g., hyperinsulinemia) that ultimately indicate risk of onset of T2D. Hyperinsulinemia and insulin resistance may often go undiagnosed but are important “prediabetic” indicators of future disease risk. Progression to overt diabetes requires a diminution in pancreatic islet β-cell mass, β-cell function, or both [1, 9, 13].

Pancreatic islet β-cells from human subjects with T2D display markers of dedifferentiation. For example, increased abundance of Aldh1a3 and reduced nuclear presence of the transcription factor Nkx6.1 were observed in pancreatic islets from T2D, but not in healthy controls [14]. Nkx6.1 is important for islet β-cell development, suppressing expression of the glucagon gene, and for maintenance of adult β-cell phenotype [15, 16]. With elevated glucagon levels being a long known feature of uncontrolled diabetes [17], it is not surprising that losses in key transcription factors within islet β-cells could lead to dysregulation of overall islet hormone production.

During a comparison of C57BL/6J mice fed a high-fat, sucrose-enriched Western diet (WD) with weight-matched genetically obese leptin receptor-deficient mice (db/db), several key findings arose: (1) WD-fed and db/db mice accumulate body weight and fat mass over time at rates higher than their respective lean control counterparts but similar to each other. (2) Both WD-fed C57BL/6J mice and db/db mice are hyperinsulinemic, but only db/db mice are hyperglycemic. (3) Circulating insulin levels are elevated in both models of obesity, but glucagon is increased only in the db/db mice. (4) While both WD-fed C57BL/6J mice and db/db mice exhibit adaptive increases in islet size, the db/db mice also display increased islet expression of the dedifferentiation marker Aldh1a3. (5) There is reduced nuclear presence of the transcription factor Nkx6.1 in db/db mice when compared with mice fed the WD. We conclude that db/db mice capture key features of human T2D that do not occur in weight-matched WD-fed C57BL/6J mice.

2. Methods

2.1. Animals and Reagents

Nine-week-old male C57BL/6J (stock number 00664) and 5-week-old male db/+ and db/db mice (B6.BKS(D)-Leprdb/J; stock number 00697) were acquired from the Jackson Laboratories (Bar Harbor, Maine). These mice were allowed to acclimate to the photoperiod (12-hour light/12-hour dark) and temperature conditions (22 ± 1°C) for one week prior to the start of the study. C57BL/6J mice were randomized into their respective dietary group assignments based on body weight and blood glucose measurements such that no significant differences existed between groups at baseline. At 10 weeks of age, 3 separate cohorts of mice were started on either control diet (Cat number 98052602; Research Diets Inc., New Brunswick, NJ) or Western diet (Cat number D12079B; Research Diets Inc.) for 4, 12, and 20 weeks. The db/db and db/+ mice were each given access to Lab Diet 5001 ad libitum throughout the study to represent conditions similar to those used for colony maintenance at the Jackson laboratory. Blood glucose was measured weekly using an Accu-Chek Aviva Plus Glucometer (Roche Diagnostic, Indianapolis, IN). Weekly measurements of body mass and composition (fat, lean, and fluid mass) were assessed by NMR using a Bruker Minispec LF50 Time-Domain NMR system. Upon completion of the study feeding period, animals were sacrificed by CO2 asphyxiation and decapitation. Whole pancreata were fixed in 10% neutral-buffered formalin overnight prior to sectioning and embedding. Fat depots, liver, and skeletal muscle were flash frozen in liquid nitrogen and stored at −80°C. Serum was collected from trunk blood or cardiac sticks. Pancreatic islets were isolated as described previously [18]. Relevant animal procedures were approved by the PBRC and the University of Tennessee Institutional Animal Care and Use Committees.

2.2. Insulin Tolerance Test, Islet Histology, and Substrate Oxidation

Mice were fasted for 2 h and were injected intraperitoneally with 0.75 units/kg Humulin R insulin as previously described [19]. Islet histology procedures have been described [19, 20]. Briefly, the antibodies used were as follows: insulin (Invitrogen; 18-0067; used at 1 : 800), glucagon (Cell Signaling Technologies; 8233; used at 1 : 400), Aldh1a3 (Novus Biologicals; NBP2-15339; used at 1 : 100), and Nkx6.1 (F55A12; 1 : 200; [21]). All antibodies were incubated overnight at 4°C and detected with either Alexa Fluor secondary conjugation (Alexa 488, 594), except for Nkx6.1, which was detected using a biotin/streptavidin exposure method. Substrate oxidation was measured in the liver, and gastrocnemius muscle homogenates were prepared and used as described previously [22, 23]. Briefly, using [1-14C] palmitate (100 μM), both complete (14CO2) and incomplete (14C-acid soluble metabolites (ASMs)) fatty acid oxidation were assessed ± varying doses of unlabeled pyruvate (0, 0.1, 1, and 10 mM) to assess metabolic flexibility.

2.3. Total RNA Extraction, cDNA Synthesis, and Real-Time RT-PCR

All procedures have been described previously [24, 25]. Briefly, total RNA was extracted from mouse islets, liver, and epididymal fat depots using an RNeasy Mini Kit (Qiagen). RNA quality and quantity was assessed using a Nanodrop spectrophotometer (Thermo Scientific). cDNA was generated from total RNA using the iScript cDNA synthesis kit (Bio-Rad). Relative mRNA abundance was measured by real-time PCR using the iTaq Universal SYBR Green Supermix (Bio-Rad) on a CFX96 instrument (Bio-Rad). Transcript levels were normalized with the housekeeping gene Ppia or Rs9. Primer pairs were designed using the Primer3Plus software.

2.4. Serum ELISA

The following kits were used to measure serum factors: Mouse/Rat Leptin Quantikine ELISA kit (Cat number MOB00) from R&D Systems (Minneapolis, MN), Mouse Insulin ELISA kit (Cat number 10-1247-01) and Glucagon ELISA kit (Cat number 10-1271-01) from Mercodia (Uppsala, Sweden), Corticosterone ELISA kit (Cat number ADI-900-097) from Enzo Life Sciences (Farmingdale, NY), and the Mouse Adiponectin ELISA kit (Cat number 80569) from Crystal Chem (Downers Grove, IL). Manufacturer’s recommended protocols were used for all serum measurements.

2.5. Tissue Acyl Glycerol Measurements

Isolated liver (30 mg) tissue was homogenized in 5% NP-40 solution (300 μL) and heated twice to 95°C to solubilize all acyl glycerol species. Samples were centrifuged at maximum speed for 2 minutes, and supernatant was removed to a clean tube to prevent contamination with insoluble material. The transferred samples were diluted 10-fold in water before proceeding with the detection portion of the assay. Acyl glycerol content was measured using the Triglyceride Determination kit (Cat number TR0100) from Sigma Aldrich according to the manufacturer’s directions.

2.6. Statistics

The data were evaluated with the GraphPad Prism 6.0 statistical analysis software. Data were analyzed by either one-way ANOVA using a Tukey post hoc, repeated measures ANOVA (for longitudinal measures of blood glucose, body weight, and body composition), two-way repeated measures ANOVA with Bonferroni post hoc test for multiple comparisons (substrate oxidation), or two-tailed Student’s t-test. Individual values are given in the figure legends.

3. Results

3.1. C57BL/6J Mice Fed a High-Fat, Sucrose-Enriched Diet Gain Weight but Do Not Develop Hyperglycemia

Over the course of 20 weeks, male C57BL/6J mice were fed either a high-fat, high-sucrose Western diet (WD) or sucrose-matched low-fat control diet (CD). Blood glucose remained stable in both groups of mice during this 20-week period (Figure 1(a)). The study conditions were closely monitored so that mice fed the WD could be weight matched with db/db mice. The db/db mice on the C57BL/6 genetic background, which develop obesity secondary to leptin resistance, display noticeable elevations in blood glucose early in their lifespan (Figure 1(b)). The db/db mice were compared to lean littermate heterozygous controls for the leptin receptor mutation (db/+). The hyperglycemia in db/db mice was maintained throughout the eight-week study period. C57BL/6J mice fed the WD gained 22.7 g of total body mass versus 13.8 g for mice fed the CD (Figures 1(c) and 1(e)). The db/db mice were fed ad libitum with a low-fat diet (6% kcal) to mimic conditions commonly used for this strain. On the low-fat diet, the db/+ animals gained 7.1 g, while db/db mice increased total body weight by 24 g (Figures 1(d) and 1(f)). Therefore, although similar accumulation of body mass was observed in C57BL/6J on a Western-style diet when compared to db/db mice on a low-fat diet, there was a noticeable difference in glycemic control between these mouse models of obesity.

3.2. db/db Mice Accumulate Adipose Tissue on a Low-Fat Diet Similar to That Seen with C57BL/6J Mice Fed a Western Diet

Because the accrual of adipose tissue (fat mass) impacts systemic metabolic parameters [6], we investigated the accumulation of this tissue depot in both diet-induced and genetic models of obesity. C57BL/6J mice fed the WD displayed consistently elevated fat mass over mice in the CD group (Figure 2(a)). We found that db/db mice between the ages of 6 and 14 weeks of age gained a similar amount of fat mass (14.5 g) as the C57BL/6J mice on a WD for 20 weeks (13.25 g; compare Figure 2(c) with Figure 2(d)). However, db/+ mice did not accumulate significant amount of fat mass between the ages of 6 and 14 weeks (0.56 g; Figures 2(b) and 2(d)), which we suspect is due to the low amount of fat and sucrose in this diet. When viewed from a perspective of fat mass as a percentage of total body mass, the C57BL/6J mice start out with a relatively low total body fat percentage (~6%) but go over 30% body fat by week 20 of WD feeding (Figure 2(e)). Alternatively, the db/db mice start out near 30% total body fat at 6 weeks of age and increased to over 40% at 14 weeks of age (Figure 2(f)). When lean mass was examined, both C57BL/6J mice fed a WD and db/db mice display similar increases in total lean mass, although the db/db mice had a lower total percentage of whole body lean mass (Figure 3). Similar findings were observed when measuring fluid mass (Figure 3).

3.3. Elevations in Serum Leptin Are Consistent with Increases in Body Weight and Adiposity in Both Models of Obesity, While Elevated Corticosterone Is Specific to db/db Mice

Leptin is a fat cell-derived hormone that has important roles in regulating satiety. Serum leptin clearly increases with body weight in WD-fed mice and is also elevated as the mice get older (Figure 4(a)). In addition, db/db mice have elevations in serum leptin over their lean counterparts (Figure 4(b)). By contrast, corticosterone is relatively stable in the serum of WD-fed mice (Figure 4(c)) but elevated in db/db mice (Figure 4(d)). Adiponectin, also derived from adipose tissue, was not impacted by body weight, adiposity, or age of the mice (Figures 4(e) and 4(f)).

3.4. There Is Clear Evidence of Inflammation in Adipose Tissue from C57BL/6J Mice Fed a WD and in db/db Mice

With clear increases in fat mass accumulation between WD and db/db mice (Figure 2(c) versus Figure 2(d)), we next measured the expression of genes involved in inflammatory responses using isolated epididymal white adipose tissue (eWAT). Expression of the Il1α gene, which encodes a proinflammatory cytokine, was strongly upregulated in animals fed WD for 12 weeks relative to mice eating the CD (Figure 5(a)). By 20 weeks, mice on the control diet were also displaying elevations in this cytokine (Figure 5(a)); in our view, this increase in inflammation in control mice is most likely due to aging. Notably, expression of IL-1α was not significantly higher in eWAT from db/db mice relative to db/+ mice (Figure 5(b)). Nucleotide-binding oligomerization (NOD) domain-like receptors (NLRs) are in the family of pattern recognition receptors and have been shown to regulate adipocyte differentiation in vitro [26]. We observed that expression of NOD1 is suppressed in mice fed the WD (Figure 5(c)) and in db/db mice relative to lean controls (Figure 5(d)). Ccl2, a chemokine that recruits monocytes and macrophages, was more highly expressed in both WD-fed mice (Figure 5(e)) and in db/db mice (Figure 5(f)), relative to their respective lean controls. Moreover, transcript levels of Cd68, a macrophage marker, were elevated at 12 weeks by WD feeding (Figure 5(g)) and also enhanced in eWAT from db/db mice (Figure 5(h)).

3.5. There Is Elevated Expression of Glucose 6-Phosphatase, Acetyl Co-A Carboxylase, and Increased Acyl Glycerols in the Liver of db/db Mice

Because severe insulin resistance in the liver is sufficient to create whole body glucose intolerance and elevations in blood glucose [27], we compared the expression of metabolic enzyme genes expressed in the livers of db/db mice and mice fed a WD. Livers from db/db mice displayed much higher expression of the gene encoding glucose 6-phosphatase (Figure 6(a)), while expression of Pck1 was similar between the obese mice (Figure 6(b)). Expression of acetyl co-A carboxylase 1 was 2.7-fold higher in db/db mice relative to mice fed a WD (Figure 6(c)), while expression of fatty acid synthase (Figure 6(d)) and stearoyl co-A desaturase 1 (Figure 6(e)) were similar between the mice. Consistent with the elevated levels of acetyl co-A carboxylase mRNA, we found that total liver acyl glycerols (mono-, di-, and tri-glycerols) were 57% higher in db/db mice relative to mice consuming the WD (Figure 6(f)). Relevant to corticosterone metabolism, the livers of WD-fed mice and db/db mice showed similar expression of the hsd11b1 gene, which encodes the enzyme 11beta-hydroxysteroid dehydrogenase 1 (Figure 6(g)). However, expression of the hsd11b2 gene was markedly reduced in db/db mice relative to mice fed the WD (Figure 6(h)).

3.6. There Is Reduced Skeletal Muscle Fat Oxidation in WD-Fed Mice, While Derangements in Both Skeletal Muscle and Liver Fat Oxidation Are Present in Weight-Matched db/db Mice

A trait observed during obesity-associated insulin resistance is the development of metabolic inflexibility, which is defined as the inability to appropriately transition between different fuel sources [28]. To test whether or not differences in metabolic flexibility occur at the tissue level in the diet-induced and genetic models of obesity, we used mixed gastrocnemius (MG) skeletal muscle and liver homogenates to measure fatty acid oxidation under conditions designed to test substrate selection (Figure 7). Compared to mice fed a control diet, MG from mice fed a Western diet had no difference in complete (CO2) palmitate oxidation (Figure 7(a)); however, MG from these mice did have elevated incomplete fatty acid oxidation rates (i.e., acid soluble metabolites (ASM); see Figure 7(b)). Alternatively, MG from db/db mice revealed higher baseline complete (Figure 7(e)) and incomplete (Figure 7(f)) palmitate oxidation than the lean db/+ controls. Interestingly, the rates of CO2 production from both db/+ and db/db mice are distinctly lower than C57BL6/J mice fed either a control or Western diet (Figure 7(a)). Importantly, palmitate oxidation rates (CO2 and ASM) in MG from both models of obesity had a main effect for pyruvate concentration indicating substrate switching; however, only genetically obese mice had an interaction effect (CO2; ASM ), indicating db/db mice exhibit a different substrate switching effect than their lean db/+ counterparts. Moreover, mice fed the control diet and Western diet (Figure 7(b)), as well as db/+ mice (Figure 7(f)), all exhibit a decrease in ASM production as pyruvate concentrations increase. However, db/db mice have a contrasting rise in incomplete palmitate oxidation under the same conditions (Figure 7(f)).

In the liver, feeding a Western diet did not alter complete (Figure 7(c)) or incomplete (Figure 7(d)) palmitate oxidation. By contrast, the liver from db/db mice have slightly lower basal CO2 production (Figure 7(g)) and clearly demonstrate substantially exaggerated incomplete fat oxidation (Figure 7(h)). As pyruvate concentrations were increased, an interaction effect was observed for complete palmitate oxidation () indicating the db/db mice had virtually a complete lack of substrate switching compared to db/+ controls (Figure 7(g)). Alternatively, no interaction effect was found concerning ASM production, indicating the impact of increasing pyruvate levels on incomplete hepatic fat oxidation was similar between db/+ and db/db mice (Figure 7(h)). It is notable that db/+ and db/db mice have lower complete hepatic palmitate oxidation rates, as well as reduced pyruvate-induced shift in hepatic fatty acid oxidation (CO2 and ASM) than C57BL6/J mice fed either a control or Western diet (Figure 7).

3.7. Circulating Insulin Levels Are Elevated in Both Models of Obesity, but Glucagon Is Only Increased in the db/db Mice

Hyperinsulinemia is present during obesity and is an independent risk factor for human disease [29, 30]. When analyzing this parameter in the obese mouse models, we found 2.5-, 2.6- and 3-fold increases in circulating levels of insulin at 4, 12, and 20 weeks, respectively, in WD-fed C57BL/6J mice compared to mice fed the control diet (Figure 8(a)). By comparison, db/db mice have 15.1-fold more insulin in circulation than their db/+ counterparts (Figure 8(b)) at 14 weeks of age. Serum insulin levels strongly correlated with both total body mass (Figures 8(c) and 8(d)) and fat mass (Figures 8(e) and 8(f)) in both diet-induced and genetic mouse models of obesity. In contrast to insulin, glucagon levels are unchanged in WD versus CD at 12 and 20 weeks of feeding (Figure 8(g)), while db/db mice displayed 87% more circulating glucagon when compared to the lean db/+ control mice (Figure 8(h)).

3.8. The Islets of db/db Mice, but Not Western Diet-Fed Mice, Display Markers of Dedifferentiation

Insulin resistance drives increases in pancreatic islet β-cell mass [9]. Therefore, we next examined islet architecture between WD-fed mice and db/db mice. Both models of obesity display increases in insulin positive area over lean control mice (Figure 9). However, islets from db/db mice display clear evidence of glucagon-positive cells within the core of the islet, which was not regularly observed in mice fed the WD (Figure 9(a)). This is consistent with an increase in glucagon transcripts within islets of db/db mice relative to WD-fed mice (not shown) and an increase in circulating glucagon in db/db mice (Figure 8(h)). In addition, we observed less immunoreactive Nkx6.1 in the nuclei of the db/db islets, which is consistent with pancreatic islets from humans with T2D [14]. By contrast, the islets of WD-fed mice retained strong evidence of nuclear Nkx6.1 expression (Figure 10(a)). Furthermore, Aldh1a3 expression was markedly elevated in db/db islets when compared with islets from WD-fed mice (Figure 10(b)). The increase in transcript is congruent with the increase in immunoreactive Adh1a3 in islets from db/db mice, but not in WD-fed C57BL/6J mice (Figure 10(c)). Taken together, these data are consistent with the premise that WD-fed mice display features of insulin resistance (e.g., islet mass expansion), while islets from db/db mice display features of T2D (e.g., elevated glucagon and indicators of dedifferentiation).

4. Discussion

There are many important signs and symptoms that indicate risk for the eventual development of T2D, including obesity, inflammation, insulin resistance, and hyperinsulinemia [4, 5, 30, 31]. The use of mouse models is important for understanding the specific pathways contributing to alterations in tissue function, insulin sensitivity, islet hormone production, β-cell proliferation, insulin resistance, and overall glucose homeostasis. Therefore, we compared two distinct models of obesity in mice, the Western diet-fed C57BL/6J mouse and the db/db mouse on the C57BL/6J genetic background. The results presented in this study have led us to conclude that in mice with similar body weights, the WD-fed C57BL/6J mouse is an excellent model of early features representing the human prediabetic condition, while the db/db mouse more closely resembles human T2D.

Elevations in circulating insulin were evident within four weeks after introduction of the WD to mice (Figure 8(a)). These data are consistent with hyperinsulinemia in db/db mice (Figure 8(b)) and observations in the human population [32]. The present findings are important because hyperinsulinemia is a risk factor for many, if not all, symptoms used to denote the metabolic syndrome [3335]. These conditions are readily recapitulated in the WD-fed mouse model and in the genetically obese db/db mice. In addition, elevated insulin levels have been suggested to be a causal factor for obesity [36, 37]. The idea that insulin influences body weight and overall adiposity is consistent with the correlations calculated for circulating insulin with total body mass (Figures 8(c) and 8(d)) and fat mass (Figures 8(e) and 8(f)) in both WD-fed and genetically obese db/db mice. Moreover, reducing insulin levels, by using diazoxide to decrease β-cell insulin output, restricts body weight in rodents by enhancing metabolic rate and increasing fat oxidation [38].

Human twin studies demonstrate that obesity has a significant genetic component [39]. In addition, there is evidence that islet β-cell failure, which is required for progression to T2D, also has a genetic basis [40]. Indeed, mutations in genes important for adult β-cell phenotype, such as GLUT2, glucokinase, NeuroD/beta2, HNF1/4, and Nkx6.1, contribute to deterioration of β-cell function in human T2D [41]. In our analyses of islets from mice fed a WD versus islets from db/db mice, we found that Nkx6.1 is reduced or absent from the nuclei of β-cells in the islets of db/db mice (Figure 9(a)). Nkx6.1 plays a key role in negatively controlling expression of the glucagon gene and therefore maintaining islet β-cells in a mature, fully differentiated state [15, 16].

The reduction in nuclear Nkx6.1 that we observe in db/db islets is also consistent with findings in pancreatic tissue from Zucker diabetic fatty rats [42] and in human subjects with T2D [14]. The increase in glucagon-positive cells we found in db/db islets (Figure 9(a)) connects changes in the pancreatic islets with the enhanced circulating glucagon in these mice (Figure 8(h)). Moreover, these data are congruent with reductions in Nkx6.1 transcripts (see [18]) and nuclear protein abundance in the islets of db/db mice (Figure 10(a)). Importantly, our findings are relevant to human disease because hyperglucagonemia is a key feature of the diabetic state [17, 43, 44]. Insulin resistance in pancreatic alpha cells may explain the elevations in circulating glucagon observed in db/db mice. Furthermore, deletion of glucagon receptors prevents hyperglycemia in obese mice with elevated glucagon [45]. We also see increases in Aldh1a3 transcript and protein in db/db islets (Figures 10(b) and 10(c)), a recently identified marker of dysfunctional and/or dedifferentiated β-cells [46]. Aldh1a3 is not elevated in the islets from WD-fed mice (Figures 10(b) and 10(c)) or any of the lean control mice (not shown), which supports our interpretation that db/db mice display phenotypes consistent with human T2D while WD-fed C57BL/6 mice may represent an earlier, nondiabetic stage of obesity and insulin resistance.

A metabolic signature of insulin-resistant skeletal muscle is an elevation in incomplete fatty acid oxidation rate, often measured as accumulation of acid soluble metabolites [22, 23]. Consistent with this notion, results from the present study show heightened ASM production in both diet-induced and genetic models of obesity. We further note that complete palmitate oxidation in db/db mice is higher than db/+ controls in the absence of pyruvate; however, when moderate (1 mM) or high (10 mM) doses of pyruvate are present, CO2 production from palmitate is similar between skeletal muscle from db/+ and db/db mice (Figure 7). At first glance, these findings are striking as they suggest that metabolic flexibility at the level of the mitochondria may actually be better in db/db mice. However, this apparent improvement seems to come at the expense of an aberrant response of incomplete fatty acid oxidation (ASMs increase in presence of higher pyruvate concentrations), suggesting that greater mitochondrial overload may be occurring in the db/db mice.

In the liver, feeding a Western diet did not alter complete (Figure 7(c)) or incomplete (Figure 7(d)) palmitate oxidation. Also, while a main effect for pyruvate concentration was observed in liver, there was no interaction effect, suggesting that the Western diet had little impact on hepatic fatty acid oxidative capacity or substrate selection at the level of the mitochondria. It is, however, worth noting that as pyruvate concentration rises, the liver of the C57BL6/J mice in the WD-fed group responds by decreasing CO2 liberation and increasing ASM production, whereas the effect of pyruvate on hepatic fat oxidation in db/+ and db/db mice is much less pronounced. Elevations in ASMs in response to increasing pyruvate levels could indicate a shift of carbons toward other metabolic outcomes (e.g., ketogenesis); however, the hyperinsulinemia induced in the diet-induced (WD fed) obese mice appears sufficient to maintain normoglycemia, which likely prevents any elevations in circulating ketones.

In adipose tissue, we detected increases in IL-1α (Figures 5(a) and 5(b)), a key cytokine that signals through the IL-1R1 and likely contributes to inflammatory responses relevant to insulin resistance. In addition, the expression of NOD1 was suppressed in both C57BL/6J mice fed the WD and db/db mice (Figures 5(c) and 5(d)). NOD1 activation blocks adipocyte differentiation in vitro [26], suggesting that this pattern recognition receptor may influence the degree of adiposity. We now provide in vivo evidence that NOD1 expression is decreased in two different mouse models of obesity, suggesting that reduced NOD1 expression is a component of adipose tissue expansion. By contrast, CCL2, a chemokine that attracts monocytes and macrophages, was elevated in adipose tissue of both WD-fed mice and db/db mice (Figures 5(e) and 5(f)). The CCL2 data are congruent with an increase in the macrophage marker CD68 (Figures 5(g) and 5(h)) and with macrophage accumulation within adipose tissue of obese rodents and humans [4749].

We note that db/db mice display elevations in both glucagon and corticosterone (Figures 4 and 8), which may explain their elevated blood glucose levels relative to mice made obese by WD feeding (Figure 1). It is possible that db/db mice have reduced ability to properly regulate their hypothalamic-pituitary-adrenal axis due to deficiencies in leptin signaling, thus producing elevations in glucose and corticosterone. This interpretation is supported by studies from the Friedman group where specific deletion of the leptin receptor in hypothalamic brain regions results in elevated plasma levels of leptin, glucose, insulin, and corticosterone [50]. Thus, physiological leptin signaling appears to be required for proper corticosterone regulation, which is supported by additional studies [51]. In addition, we observed much less mRNA encoding for the 11-β-hydroxysteroid dehydrogenase 2 enzyme (Figure 6(h)). Since this enzyme is responsible for converting active steroid to inactive steroid, this observation could help to explain the elevations in circulating corticosterone or prolonged actions of the hormone in db/db mice. Finally, elevations in corticosterone and glucagon present in the db/db mice, but not the mice fed a WD, are consistent with the higher blood glucose observed in db/db mice.

In summary, we conducted a systematic analysis of two fundamental mouse models of obesity, one representing early stages of insulin resistance (WD fed) and the other displaying key features of overt T2D (db/db). With various pharmacologic, dietary, and exercise-based interventions being pursued to prevent or reverse the obese and insulin resistance state, our novel results are intended to provide a convenient resource for choosing a mouse model that best mimics the desired stage of human disease to be studied.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


The authors would like to thank Thomas Martin for technical assistance. The authors also thank the staff of the PBRC Comparative Biology and Cell Biology and Bioimaging Cores for their technical assistance and support. This work was supported by NIH Grants P20-GM103528 (J. Jason Collier) and R01-DK103860 (Robert C. Noland) and a grant from the Physician Medical Education Research Foundation, Knoxville (Matthew S. Boulos, Michael D. Karlstad, and J. Jason Collier). This study used the PBRC Cell Biology and Bioimaging Core Facilities that are supported in part by COBRE (P30-GM118430-01) and NORC (NIH P30-DK072476) center grants from the National Institutes of Health.


  1. D. M. Muoio and C. B. Newgard, “Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 193–205, 2008. View at: Publisher Site | Google Scholar
  2. V. T. Samuel and G. I. Shulman, “Mechanisms for insulin resistance: common threads and missing links,” Cell, vol. 148, no. 5, pp. 852–871, 2012. View at: Publisher Site | Google Scholar
  3. G. A. Bray, “Overweight is risking fate. Definition, classification, prevalence, and risks,” Annals of the New York Academy of Sciences, vol. 499, pp. 14–28, 1987. View at: Google Scholar
  4. G. A. Bray, “Obesity increases risk for diabetes,” International Journal of Obesity and Related Metabolic Disorders, vol. 16, Supplement 4, pp. S13–S17, 1992. View at: Google Scholar
  5. M. F. Gregor and G. S. Hotamisligil, “Inflammatory mechanisms in obesity,” Annual Review of Immunology, vol. 29, pp. 415–445, 2011. View at: Publisher Site | Google Scholar
  6. J. H. Stern, J. M. Rutkowski, and P. E. Scherer, “Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk,” Cell Metabolism, vol. 23, no. 5, pp. 770–784, 2016. View at: Publisher Site | Google Scholar
  7. R. H. Unger, “Lipotoxic diseases,” Annual Review of Medicine, vol. 53, pp. 319–336, 2002. View at: Publisher Site | Google Scholar
  8. R. H. Unger and L. Orci, “Diseases of liporegulation: new perspective on obesity and related disorders,” The FASEB Journal, vol. 15, no. 2, pp. 312–321, 2001. View at: Publisher Site | Google Scholar
  9. S. J. Burke, M. D. Karlstad, and J. J. Collier, “Pancreatic islet responses to metabolic trauma,” Shock, vol. 46, no. 3, pp. 230–238, 2016. View at: Publisher Site | Google Scholar
  10. Y. Dor, J. Brown, O. I. Martinez, and D. A. Melton, “Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation,” Nature, vol. 429, no. 6987, pp. 41–46, 2004. View at: Publisher Site | Google Scholar
  11. R. B. Sharma, A. C. O'Donnell, R. E. Stamateris et al., “Insulin demand regulates beta cell number via the unfolded protein response,” The Journal of Clinical Investigation, vol. 125, no. 10, pp. 3831–3846, 2015. View at: Publisher Site | Google Scholar
  12. S. E. Kahn, S. Zraika, K. M. Utzschneider, and R. L. Hull, “The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality,” Diabetologia, vol. 52, no. 6, pp. 1003–1012, 2009. View at: Publisher Site | Google Scholar
  13. B. B. Kahn, “Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance,” Cell, vol. 92, no. 5, pp. 593–596, 1998. View at: Google Scholar
  14. F. Cinti, R. Bouchi, J. Y. Kim-Muller et al., “Evidence of beta-cell dedifferentiation in human type 2 diabetes,” The Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 3, pp. 1044–1054, 2016. View at: Publisher Site | Google Scholar
  15. J. C. Schisler, P. B. Jensen, D. G. Taylor et al., “The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 20, pp. 7297–7302, 2005. View at: Publisher Site | Google Scholar
  16. B. L. Taylor, F. F. Liu, and M. Sander, “Nkx6.1 is essential for maintaining the functional state of pancreatic beta cells,” Cell Reports, vol. 4, no. 6, pp. 1262–1275, 2013. View at: Publisher Site | Google Scholar
  17. R. H. Unger and L. Orci, “The essential role of glucagon in the pathogenesis of diabetes mellitus,” Lancet, vol. 1, no. 7897, pp. 14–16, 1975. View at: Google Scholar
  18. S. J. Burke, M. D. Karlstad, K. M. Regal et al., “CCL20 is elevated during obesity and differentially regulated by NF-kappaB subunits in pancreatic beta-cells,” Biochimica et Biophysica Acta, vol. 1849, no. 6, pp. 637–652, 2015. View at: Publisher Site | Google Scholar
  19. S. J. Burke, H. M. Batdorf, A. E. Eder et al., “Oral corticosterone administration reduces insulitis but promotes insulin resistance and hyperglycemia in male nonobese diabetic mice,” The American Journal of Pathology, vol. 187, no. 3, pp. 614–626, 2017. View at: Publisher Site | Google Scholar
  20. S. J. Burke, M. D. Karlstad, A. E. Eder et al., “Pancreatic beta-cell production of CXCR3 ligands precedes diabetes onset,” BioFactors, vol. 42, no. 6, pp. 703–715, 2016. View at: Publisher Site | Google Scholar
  21. R. Klinck, P. Serup, O. D. Madsen, and M. C. Jorgensen, “Specificity of four monoclonal anti-NKx6-1 antibodies,” The Journal of Histochemistry and Cytochemistry, vol. 56, no. 4, pp. 415–424, 2008. View at: Publisher Site | Google Scholar
  22. R. C. Noland, T. R. Koves, S. E. Seiler et al., “Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control,” The Journal of Biological Chemistry, vol. 284, no. 34, pp. 22840–22852, 2009. View at: Publisher Site | Google Scholar
  23. T. R. Koves, J. R. Ussher, R. C. Noland et al., “Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance,” Cell Metabolism, vol. 7, no. 1, pp. 45–56, 2008. View at: Publisher Site | Google Scholar
  24. S. J. Burke, J. J. Collier, and D. K. Scott, “cAMP prevents glucose-mediated modifications of histone H3 and recruitment of the RNA polymerase II holoenzyme to the L-PK gene promoter,” Journal of Molecular Biology, vol. 392, no. 3, pp. 578–588, 2009. View at: Publisher Site | Google Scholar
  25. D. K. Scott, J. J. Collier, T. T. Doan et al., “A modest glucokinase overexpression in the liver promotes fed expression levels of glycolytic and lipogenic enzyme genes in the fasted state without altering SREBP-1c expression,” Molecular and Cellular Biochemistry, vol. 254, no. 1-2, pp. 327–337, 2003. View at: Google Scholar
  26. J. Purohit, P. Hu, S. J. Burke, J. J. Collier, J. Chen, and L. Zhao, “The effects of NOD activation on adipocyte differentiation,” Obesity (Silver Spring), vol. 21, no. 4, pp. 737–747, 2013. View at: Publisher Site | Google Scholar
  27. M. D. Michael, R. N. Kulkarni, C. Postic et al., “Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction,” Molecular Cell, vol. 6, no. 1, pp. 87–97, 2000. View at: Google Scholar
  28. J. E. Galgani, C. Moro, and E. Ravussin, “Metabolic flexibility and insulin resistance,” American Journal of Physiology, Endocrinology and Metabolism, vol. 295, no. 5, pp. E1009–E1017, 2008. View at: Google Scholar
  29. J. P. Despres, B. Lamarche, P. Mauriege et al., “Hyperinsulinemia as an independent risk factor for ischemic heart disease,” The New England Journal of Medicine, vol. 334, no. 15, pp. 952–957, 1996. View at: Publisher Site | Google Scholar
  30. B. Jeanrenaud, “Hyperinsulinemia in obesity syndromes: its metabolic consequences and possible etiology,” Metabolism, vol. 27, no. 12, Supplement 2, pp. 1881–1892, 1978. View at: Google Scholar
  31. S. M. Haffner, “Hyperinsulinemia as a possible etiology for the high prevalence of non insulin dependent diabetes in Mexican Americans,” Diabète & Métabolisme, vol. 13, no. 3, Part 2, pp. 337–344, 1987. View at: Google Scholar
  32. C. Crofts, G. Schofield, C. Zinn, M. Wheldon, and J. Kraft, “Identifying hyperinsulinaemia in the absence of impaired glucose tolerance: an examination of the Kraft database,” Diabetes Research and Clinical Practice, vol. 118, pp. 50–57, 2016. View at: Publisher Site | Google Scholar
  33. P. Xun, Y. Wu, Q. He, and K. He, “Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies,” The American Journal of Clinical Nutrition, vol. 98, no. 6, pp. 1543–1554, 2013. View at: Publisher Site | Google Scholar
  34. K. C. Sung, M. H. Seo, E. J. Rhee, and A. M. Wilson, “Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study,” Cardiovascular Diabetology, vol. 10, p. 108, 2011. View at: Publisher Site | Google Scholar
  35. O. E. Odeleye, M. de Courten, D. J. Pettitt, and E. Ravussin, “Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children,” Diabetes, vol. 46, no. 8, pp. 1341–1345, 1997. View at: Google Scholar
  36. A. E. Mehran, N. M. Templeman, G. S. Brigidi et al., “Hyperinsulinemia drives diet-induced obesity independently of brain insulin production,” Cell Metabolism, vol. 16, no. 6, pp. 723–737, 2012. View at: Publisher Site | Google Scholar
  37. R. H. Unger, “Reinventing type 2 diabetes: pathogenesis, treatment, and prevention,” The Journal of the American Medical Association, vol. 299, no. 10, pp. 1185–1187, 2008. View at: Publisher Site | Google Scholar
  38. R. Alemzadeh, M. D. Karlstad, K. Tushaus, and M. Buchholz, “Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats,” Metabolism, vol. 57, no. 11, pp. 1597–1607, 2008. View at: Publisher Site | Google Scholar
  39. A. J. Stunkard, T. T. Foch, and Z. Hrubec, “A twin study of human obesity,” The Journal of the American Medical Association, vol. 256, no. 1, pp. 51–54, 1986. View at: Google Scholar
  40. J. C. Florez, “Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes?” Diabetologia, vol. 51, no. 7, pp. 1100–1110, 2008. View at: Publisher Site | Google Scholar
  41. T. M. Frayling, J. C. Evans, M. P. Bulman et al., “Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors,” Diabetes, vol. 50, Supplement 1, pp. S94–S100, 2001. View at: Google Scholar
  42. S. J. Burke, K. Stadler, D. Lu et al., “IL-1beta reciprocally regulates chemokine and insulin secretion in pancreatic beta-cells via NF-kappaB,” American Journal of Physiology, Endocrinology and Metabolism, vol. 309, no. 8, pp. E715–E726, 2015. View at: Publisher Site | Google Scholar
  43. R. H. Unger and A. D. Cherrington, “Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover,” The Journal of Clinical Investigation, vol. 122, no. 1, pp. 4–12, 2012. View at: Publisher Site | Google Scholar
  44. P. Raskin and R. H. Unger, “Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes,” The New England Journal of Medicine, vol. 299, no. 9, pp. 433–436, 1978. View at: Publisher Site | Google Scholar
  45. Y. Lee, E. D. Berglund, X. Yu et al., “Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 36, pp. 13217–13222, 2014. View at: Publisher Site | Google Scholar
  46. J. Y. Kim-Muller, J. Fan, Y. J. Kim et al., “Aldehyde dehydrogenase 1a3 defines a subset of failing pancreatic beta cells in diabetic mice,” Nature Communications, vol. 7, article 12631, 2016. View at: Publisher Site | Google Scholar
  47. S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding,” The Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124, 2006. View at: Publisher Site | Google Scholar
  48. C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces a phenotypic switch in adipose tissue macrophage polarization,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 175–184, 2007. View at: Publisher Site | Google Scholar
  49. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. View at: Publisher Site | Google Scholar
  50. P. Cohen, C. Zhao, X. Cai et al., “Selective deletion of leptin receptor in neurons leads to obesity,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1113–1121, 2001. View at: Publisher Site | Google Scholar
  51. F. P. Pralong, R. Roduit, G. Waeber et al., “Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland,” Endocrinology, vol. 139, no. 10, pp. 4264–4268, 1998. View at: Publisher Site | Google Scholar

Copyright © 2017 Susan J. Burke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2932 Views | 854 Downloads | 18 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.